CDC Guidelines for Chronic Suppressive Therapy of Recurrent Genital Herpes in Immunocompetent Adults
Recommended Regimens
The Centers for Disease Control and Prevention (CDC) recommends daily suppressive therapy with valacyclovir 500 mg once daily (or 1 g once daily for patients experiencing ≥ 10 recurrences per year), acyclovir 400 mg twice daily, or famciclovir 250 mg twice daily in immunocompetent adults 1, 2, 3.
For patients with ≥ 10 recurrences per year, valacyclovir 1 g once daily is preferred because the 500‑mg dose is less effective in this high‑frequency group 1, 2, 3.
Acyclovir 400 mg twice daily is endorsed for its longest safety record, with documented efficacy maintained for up to six years of continuous use 1.
Famciclovir 250 mg twice daily is an accepted alternative regimen 1, 2, 3.
Valacyclovir and famciclovir provide more convenient, less‑frequent dosing than acyclovir, which may enhance long‑term adherence for chronic therapy 1.
Efficacy and Safety
Daily suppressive therapy reduces the frequency of genital‑herpes recurrences by ≥ 75 % in patients with frequent recurrences (defined as ≥ 6 episodes per year) 1, 2, 3.
Acyclovir has demonstrated safety and efficacy for up to six years of uninterrupted use 1, 2, 3.
Valacyclovir and famciclovir have documented safety data for at least one year, with clinical experience now extending beyond that period 1.
Suppressive therapy has not been associated with the emergence of clinically significant acyclovir resistance in immunocompetent patients 1, 2, 3.
Treatment Duration and Reassessment
After one year of continuous suppressive therapy, treatment should be temporarily discontinued to reassess the patient’s recurrence rate, as many patients experience a natural decline in episode frequency over time 1, 2, 3.
Reassessment serves to (1) evaluate the patient’s psychological adjustment to genital herpes and (2) determine whether continued suppression remains necessary based on the current recurrence frequency 1.
Transmission Risk
- Suppressive acyclovir reduces but does not eliminate asymptomatic viral shedding, so the risk of HSV transmission to sexual partners persists even while on therapy 1, 2, 3.
Clinical Pitfalls and Counseling Points
Do not use valacyclovir 500 mg once daily in patients with ≥ 10 recurrences per year; the higher 1 g dose is required for adequate efficacy 1, 2, 3.
Do not continue suppressive therapy indefinitely without periodic reassessment, because recurrence frequency often decreases over time, making ongoing suppression potentially unnecessary 1.
Acyclovir Dosage for Herpes Simplex Virus Infections
Standard Suppressive Therapy Dosing
- The Centers for Disease Control and Prevention (CDC) recommends acyclovir 400 mg orally twice daily as the standard suppressive regimen for recurrent genital herpes 4, 5
- The CDC guidelines also suggest an alternative regimen of acyclovir 200 mg orally 3-5 times daily for dose titration to the lowest effective dose 6
Clinical Efficacy and Duration
- Daily suppressive therapy with acyclovir reduces genital herpes recurrence frequency by ≥75% in patients with frequent recurrences (≥6 episodes per year) 4, 5
- The safety and efficacy of continuous acyclovir therapy have been documented for up to 6 years 4, 5
- After 1 year of continuous suppressive therapy, discontinuation should be discussed to reassess recurrence rate, as frequency often decreases over time 4, 5
- Suppressive therapy has not been associated with clinically significant acyclovir resistance in immunocompetent patients 4, 5
Important Caveats
- Suppressive acyclovir reduces but does not eliminate asymptomatic viral shedding, so transmission risk remains 4, 5
- The medication does not eradicate latent virus or affect subsequent recurrence risk after discontinuation 6
- Valacyclovir and famciclovir offer alternative suppressive options with less frequent dosing (once or twice daily), which may improve adherence for prolonged treatment 4